ArticleThe oncologist2026
Proactive identification of candidates for newly approved targeted therapies using a clinical decision support program.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComprehensive molecular profiling (CMP) enables identification of multiple biomarkers from a single sample to inform targeted therapy selection. However, the static nature of test reports limits their clinical relevance as new therapies emerge. Based on the presence of molecular alterations, the population of patients qualifying for FDA-approved therapies nearly doubled since 2017, while FDA-recognized biomarkers of drug response quadrupled. Lookback programs are clinical decision support services designed to notify clinicians when previously profiled patients become candidates for new targeted therapies based on original test results. This study describes biomarkers assessed in a lookback program and summarizes identification of patients who become candidates for novel treatment options following new FDA approvals. MATERIALS AND
methodsBetween 2018 and 2025, tumor samples were submitted to Caris Life Sciences for whole-exome sequencing, whole-transcriptome sequencing, and immunohistochemistry. With new biomarker-directed approvals, the support tool is prompted to evaluate indications as candidates for lookbacks. For approved candidates, molecular profiles from the database are retrospectively assessed for relevant biomarker status within disease-site context. After evaluation, a molecular scientist sends standardized communication informing oncologists of potential candidates for the new therapy.
resultsSince 2018, 87 biomarker-directed FDA approvals were evaluated for the lookback program. Among 483 000 molecular profiles, 13 293 patients were identified as candidates for newly approved agents in ten distinct tumor types and several tumor-agnostic indications.
conclusionsBy coupling CMP with continuous evidence surveillance and proactive provider clinician engagement, lookback programs potentially close the gap between therapeutic innovation and clinical application by providing timely information about emerging targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.